The advent of pandemic flu and bioterrorism threats has accentuated the need for rapid deployment biomanufacturing as well as rapid drug discovery, and current biomanufacturing facilities and technologies are too inflexible. This session will present the strategies and technologies that the government and industry are pursuing to address this critical aspect of biodefense.



Objectives:

Introduce speed as a strategic asset in biodefense and pandemic response, including drug discovery and biomanufacturing drug supply. Review preparedness of traditional approaches to drug development and supply.

Outline U.S. government and industry initiatives that are under way to help develop rapid response and deployment technologies in biomanufacturing.

Introduce examples of advanced rapid deployment biomanufacturing technologies.